Simple blood test may predict deadly transplant complication
NCT ID NCT05718791
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether two blood markers, CXCL9 and EASIX, can predict severe acute graft-versus-host disease (GVHD) after a stem cell transplant. Researchers will take blood samples from 100 adult patients 28 days after transplant to see if these markers can spot early signs of GVHD. The goal is to help doctors make better decisions and improve transplant success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a simple blood test that helps doctors predict and prevent severe graft-versus-host disease before it starts.
What could go wrong
This is a small, early-stage study (100 participants) that only measures markers at one time point. The results may not apply to all patients or lead to a reliable prediction tool.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henry Ford Health System
RECRUITINGDetroit, Michigan, 48202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••